Gut microbiota: Implications in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 38, Issue , 2017, Pages 1-7

  Parashar, Arun ^a   Udayabanu, Malairaman ^a  

^a JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

Author keywords

Antibiotics; Fecal transplant; Germ free; Gut microbiota; Parkinson's disease; Probiotics

Indexed keywords

CEFTRIAXONE; METRONIDAZOLE; MINOCYCLINE; POLYMYXIN B; POSTSYNAPTIC DENSITY PROTEIN 95; PROBIOTIC AGENT; SYNAPTOPHYSIN; ANTIINFECTIVE AGENT;

AUTONOMIC NERVOUS SYSTEM; COGNITION; CORPUS STRIATUM; DISEASE ASSOCIATION; DOPAMINE METABOLISM; DYSBIOSIS; FRONTAL CORTEX; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; INTESTINE FLORA; LIMBIC CORTEX; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; REVIEW; TISSUE DISTRIBUTION; ANIMAL; DRUG EFFECTS; MICROBIOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; COGNITION; GASTROINTESTINAL MICROBIOME; HUMANS; PARKINSON DISEASE; PROBIOTICS;

EID: 85012014046     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2017.02.002     Document Type: Review

References (108)

1. [1] Franzosa, E.A., Huang, K., Meadow, J.F., Gevers, D., Lemon, K.P., Bohannan, B.J., Huttenhower, C., Identifying personal microbiomes using metagenomic codes. Proc. Natl. Acad. Sci. U. S. A. 112:22 (2015), E2930–E2938.
2. [2] Walker, A.W., Duncan, S.H., Louis, P., Flint, H.J., Phylogeny, culturing, and metagenomics of the human gut microbiota. Trends Microbiol. 22:5 (2014), 267–274.
3. [3] Browne, H.P., Forster, S.C., Anonye, B.O., Kumar, N., Neville, B.A., Stares, M.D., Goulding, D., Lawley, T.D., Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature 533:7604 (2016), 543–546.
4. [4] Nicholson, J.K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., Pettersson, S., Host-gut microbiota metabolic interactions. Science 336:6086 (2012), 1262–1267.
5. [5] Cryan, J.F., Dinan, T.G., Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13:10 (2012), 701–712.
6. [6] Tillisch, K., Labus, J., Kilpatrick, L., Jiang, Z., Stains, J., Ebrat, B., Guyonnet, D., Legrain–Raspaud, S., Trotin, B., Naliboff, B., Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 144:7 (2013), 1394–1401 e4.
7. [7] Diaz Heijtz, R., Wang, S., Anuar, F., Qian, Y., Bjorkholm, B., Samuelsson, A., Hibberd, M.L., Forssberg, H., Pettersson, S., Normal gut microbiota modulates brain development and behavior. Proc. Natl. Acad. Sci. U. S. A. 108:7 (2011), 3047–3052.
8. [8] Forsythe, P., Kunze, W.A., Voices from within: gut microbes and the CNS. Cell. Mol. Life Sci. 70:1 (2013), 55–69.
9. [9] Bercik, P., Denou, E., Collins, J., Jackson, W., Lu, J., Jury, J., Deng, Y., Blennerhassett, P., Macri, J., McCoy, K.D., Verdu, E.F., Collins, S.M., The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 141:2 (2011), 599–609 609 e1–3.
10. [10] Wolters, E., Braak, H., Parkinson's disease: premotor clinico-pathological correlations. J. Neural Transm.(70), 2006, 309–319.
11. [11] Sulzer, D., Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 30:5 (2007), 244–250.
12. [12] Del Tredici, K., Rub, U., De Vos, R.A., Bohl, J.R., Braak, H., Where does parkinson disease pathology begin in the brain?. J. neuropathology Exp. neurology 61:5 (2002), 413–426.
13. [13] Ueki, A., Otsuka, M., Life style risks of Parkinson's disease: association between decreased water intake and constipation. J. neurology, 251(7), 2004 vii18-vii23.
14. [14] Noyce, A.J., Bestwick, J.P., Silveira-Moriyama, L., Hawkes, C.H., Giovannoni, G., Lees, A.J., Schrag, A., Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurology 72:6 (2012), 893–901.
15. [15] Poewe, W., Non-motor symptoms in Parkinson's disease. Eur. J. Neurology 15:s1 (2008), 14–20.
16. [16] Cersosimo, M.G., Benarroch, E.E., Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol. Dis. 46:3 (2012), 559–564.
17. [17] Forsyth, C.B., Shannon, K.M., Kordower, J.H., Voigt, R.M., Shaikh, M., Jaglin, J.A., Estes, J.D., Dodiya, H.B., Keshavarzian, A., Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One, 6(12), 2011 e28032.
18. [18] Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., Bruley des Varannes, S., Naveilhan, P., Nguyen, J.M., Neunlist, M., Derkinderen, P., Colonic inflammation in Parkinson's disease. Neurobiol. Dis. 50 (2013), 42–48.
19. [19] Braak, H., de Vos, R.A., Bohl, J., Del Tredici, K., Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396:1 (2006), 67–72.
20. [20] Shannon, K.M., Keshavarzian, A., Dodiya, H.B., Jakate, S., Kordower, J.H., Is alpha-synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases. Mov. Disord. 27:6 (2012), 716–719.
21. [21] Kieburtz, K., Wunderle, K.B., Parkinson's disease: evidence for environmental risk factors. Mov. Disord. Official J. Mov. Disord. Soc. 28:1 (2013), 8–13.
22. [22] Savica, R., Carlin, J.M., Grossardt, B.R., Bower, J.H., Ahlskog, J.E., Maraganore, D.M., Bharucha, A.E., Rocca, W.A., Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73:21 (2009), 1752–1758.
23. [23] Camci, G., Oguz, S., Association between Parkinson's disease and helicobacter pylori. J. Clin. Neurol. 12:2 (2016), 147–150.
24. [24] Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M.A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., Di Giacopo, R., Campanale, M., Gigante, G., Lauritano, E.C., Navarra, P., Marconi, S., Gasbarrini, A., Bentivoglio, A.R., The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov. Disord. Official J. Mov. Disord. Soc. 28:9 (2013), 1241–1249.
25. [25] Tan, A.H., Mahadeva, S., Thalha, A.M., Gibson, P.R., Kiew, C.K., Yeat, C.M., Ng, S.W., Ang, S.P., Chow, S.K., Tan, C.T., Yong, H.S., Marras, C., Fox, S.H., Lim, S.Y., Small intestinal bacterial overgrowth in Parkinson's disease. Park. Relat. Disord. 20:5 (2014), 535–540.
26. [26] Scheperjans, F., Aho, V., Pereira, P.A., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola-Rautio, J., Pohja, M., Kinnunen, E., Murros, K., Auvinen, P., Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov. Disord. Official J. Mov. Disord. Soc. 30:3 (2015), 350–358.
27. [27] Keshavarzian, A., Green, S.J., Engen, P.A., Voigt, R.M., Naqib, A., Forsyth, C.B., Mutlu, E., Shannon, K.M., Colonic bacterial composition in Parkinson's disease. Mov. Disord. Official J. Mov. Disord. Soc. 30:10 (2015), 1351–1360.
28. [28] Derkinderen, P., Shannon, K.M., Brundin, P., Gut feelings about smoking and coffee in Parkinson's disease. Mov. Disord. 29:8 (2014), 976–979.
29. [29] Thakur, A.K., Shakya, A., Husain, G.M., Emerald, M., Kumar, V., Gut-microbiota and mental health: current and future perspectives. J. Pharmacol. Clin. Toxicol., 2, 2014, 1016.
30. [30] Eisenhofer, G., Aneman, A., Friberg, P., Hooper, D., Fandriks, L., Lonroth, H., Hunyady, B., Mezey, E., Substantial production of dopamine in the human gastrointestinal tract. J. Clin. Endocrinol. Metabolism 82:11 (1997), 3864–3871.
31. [31] Wall, R., Cryan, J.F., Ross, R.P., Fitzgerald, G.F., Dinan, T.G., Stanton, C., Bacterial neuroactive compounds produced by psychobiotics. Adv. Exp. Med. Biol. 817 (2014), 221–239.
32. [32] Matsumoto, M., Kibe, R., Ooga, T., Aiba, Y., Sawaki, E., Koga, Y., Benno, Y., Cerebral low-molecular metabolites influenced by intestinal microbiota: a pilot study. Front. Syst. Neurosci., 7, 2013, 9.
33. [33] Neufeld, K.A., Kang, N., Bienenstock, J., Foster, J.A., Effects of intestinal microbiota on anxiety-like behavior. Commun. Integr. Biol. 4:4 (2011), 492–494.
34. [34] Nishino, R., Mikami, K., Takahashi, H., Tomonaga, S., Furuse, M., Hiramoto, T., Aiba, Y., Koga, Y., Sudo, N., Commensal microbiota modulate murine behaviors in a strictly contamination-free environment confirmed by culture-based methods. Neurogastroenterol. Motil. Official J. Eur. Gastrointest. Motil. Soc. 25:6 (2013), 521–528.
35. [35] Crumeyrolle-Arias, M., Jaglin, M., Bruneau, A., Vancassel, S., Cardona, A., Dauge, V., Naudon, L., Rabot, S., Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats. Psychoneuroendocrinology 42 (2014), 207–217.
36. [36] Daubner, S.C., Le, T., Wang, S., Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys. 508:1 (2011), 1–12.
37. [37] Bateup, H.S., Santini, E., Shen, W., Birnbaum, S., Valjent, E., Surmeier, D.J., Fisone, G., Nestler, E.J., Greengard, P., Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc. Natl. Acad. Sci. 107:33 (2010), 14845–14850.
38. [38] Sampson, T.R., Debelius, J.W., Thron, T., Janssen, S., Shastri, G.G., Ilhan, Z.E., Challis, C., Schretter, C.E., Rocha, S., Gradinaru, V., Chesselet, M.F., Keshavarzian, A., Shannon, K.M., Krajmalnik-Brown, R., Wittung-Stafshede, P., Knight, R., Mazmanian, S.K., Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167:6 (2016), 1469–1480 e12.
39. [39] Du, Y., Ma, Z., Lin, S., Dodel, R.C., Gao, F., Bales, K.R., Triarhou, L.C., Chernet, E., Perry, K.W., Nelson, D.L., Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. 98:25 (2001), 14669–14674.
40. [40] Radad, K., Moldzio, R., Rausch, W.-D., Minocycline protects dopaminergic neurons against long-term rotenone toxicity. Can. J. Neurological Sci. 37:01 (2010), 81–85.
41. [41] Faust, K., Gehrke, S., Yang, Y., Yang, L., Beal, M.F., Lu, B., Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci., 10, 2009, 109.
42. [42] Inamdar, A.A., Chaudhuri, A., O'Donnell, J., The protective effect of minocycline in a paraquat-induced Parkinson's disease model in Drosophila is modified in altered genetic backgrounds. Parkinson's Dis., 2012, 2012.
43. [43] Investigators, N.N.-P., A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:5 (2006), 664–671.
44. [44] Yang, L., Sugama, S., Chirichigno, J.W., Gregorio, J., Lorenzl, S., Shin, D.H., Browne, S.E., Shimizu, Y., Joh, T.H., Beal, M.F., Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res. 74:2 (2003), 278–285.
45. [45] Diguet, E., Fernagut, P.O., Wei, X., Du, Y., Rouland, R., Gross, C., Bezard, E., Tison, F., Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur. J. Neurosci. 19:12 (2004), 3266–3276.
46. [46] Kosiewicz, M.M., Zirnheld, A.L., Alard, P., Gut microbiota, immunity, and disease: a complex relationship. Front. Microbiol., 2, 2011.
47. [47] Stone, M., Fortin, P.R., Pacheco-Tena, C., Inman, R.D., Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J. Rheumatology 30:10 (2003), 2112–2122.
48. [48] Yang, T., Santisteban, M.M., Rodriguez, V., Li, E., Ahmari, N., Carvajal, J.M., Zadeh, M., Gong, M., Qi, Y., Zubcevic, J., Gut dysbiosis is linked to hypertension. Hypertension 65:6 (2015), 1331–1340.
49. [49] Lotan, D., Cunningham, M., Joel, D., Antibiotic Treatment Attenuates Behavioral and Neurochemical Changes Induced by Exposure of Rats to Group a Streptococcal Antigen. 2014.
50. [50] Tallarida, C.S., Corley, G., Kovalevich, J., Yen, W., Langford, D., Rawls, S.M., Ceftriaxone attenuates locomotor activity induced by acute and repeated cocaine exposure in mice. Neurosci. Lett. 556 (2013), 155–159.
51. [51] Davey, K., Cotter, P., O'Sullivan, O., Crispie, F., Dinan, T., Cryan, J., O'Mahony, S., Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl. psychiatry, 3(10), 2013 e309.
52. [52] Borody, T., Torres, M., Campbell, J., Hills, L., Ketheeswaran, S., Treatment of Severe Constipation Improves Parkinson's Disease (PD) Symptoms, American Journal of Gastroenterology. 2009, NATURE PUBLISHING GROUP, 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA, S367.
53. [53] Surwase, S.N., Jadhav, J.P., Bioconversion of L-tyrosine to L-DOPA by a novel bacterium Bacillus sp. JPJ, Amino acids 41:2 (2011), 495–506.
54. [54] Hwang, O., Role of oxidative stress in Parkinson's disease. Exp. Neurobiol. 22:1 (2013), 11–17.
55. [55] Jenner, P., Oxidative stress in Parkinson's disease. Ann. Neurology 53:S3 (2003), S26–S38.
56. [56] Zhang, S.M., Hernan, M.A., Chen, H., Spiegelman, D., Willett, W.C., Ascherio, A., Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59:8 (2002), 1161–1169.
57. [57] Miyake, Y., Fukushima, W., Tanaka, K., Sasaki, S., Kiyohara, C., Tsuboi, Y., Yamada, T., Oeda, T., Miki, T., Kawamura, N., Sakae, N., Fukuyama, H., Hirota, Y., Nagai, M., Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan. Eur. J. neurology Official J. Eur. Fed. Neurological Soc. 18:1 (2011), 106–113.
58. [58] Lan, J., Jiang, D.H., Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. 104:4–5 (1997), 469–481.
59. [59] Storch, A., Kaftan, A., Burkhardt, K., Schwarz, J., 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J. Neural Transm. 107:3 (2000), 281–293.
60. [60] Suzuki, M., Yoshioka, M., Hashimoto, M., Murakami, M., Noya, M., Takahashi, D., Urashima, M., Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am. J. Clin. Nutr. 97:5 (2013), 1004–1013.
61. [61] Wang, J.Y., Wu, J.N., Cherng, T.L., Hoffer, B.J., Chen, H.H., Borlongan, C.V., Wang, Y., Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 904:1 (2001), 67–75.
62. [62] Smith, M.P., Fletcher-Turner, A., Yurek, D.M., Cass, W.A., Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem. Res. 31:4 (2006), 533–539.
63. [63] Holick, M.F., Vitamin D deficiency. N. Engl. J. Med. 357:3 (2007), 266–281.
64. [64] Coimbra, C., Junqueira, V., High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients. Braz. J. Med. Biol. Res. 36:10 (2003), 1409–1417.
65. [65] Murakami, K., Miyake, Y., Sasaki, S., Tanaka, K., Fukushima, W., Kiyohara, C., Tsuboi, Y., Yamada, T., Oeda, T., Miki, T., Kawamura, N., Sakae, N., Fukuyama, H., Hirota, Y., Nagai, M., Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: a case-control study in Japan. Br. J. Nutr. 104:5 (2010), 757–764.
66. [66] Hill, M.J., Intestinal flora and endogenous vitamin synthesis. Eur. J. Cancer Prev. 6:1 (1997), S43–S45.
67. [67] LeBlanc, J.G., Milani, C., de Giori, G.S., Sesma, F., van Sinderen, D., Ventura, M., Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr. Opin. Biotechnol. 24:2 (2013), 160–168.
68. [68] Deguchi, Y., Morishita, T., Mutai, M., Comparative studies on synthesis of water-soluble vitamins among human species of bifidobacteria. Agric. Biol. Chem. 49:1 (1985), 13–19.
69. [69] Noda, H., Akasaka, N., Ohsugi, M., Biotin production by bifidobacteria. J. Nutr. Sci. vitaminology 40:2 (1994), 181–188.
70. [70] Pompei, A., Cordisco, L., Amaretti, A., Zanoni, S., Matteuzzi, D., Rossi, M., Folate production by bifidobacteria as a potential probiotic property. Appl. Environ. Microbiol. 73:1 (2007), 179–185.
71. [71] Cassani, E., Privitera, G., Pezzoli, G., Pusani, C., Madio, C., Iorio, L., Barichella, M., Use of probiotics for the treatment of constipation in Parkinson's disease patients. Minerva Gastroenterol. Dietol. 57:2 (2011), 117–121.
72. [72] Aas, J., Gessert, C.E., Bakken, J.S., Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. Official Publ. Infect. Dis. Soc. Am. 36:5 (2003), 580–585.
73. [73] Abbott, R.D., Petrovitch, H., White, L.R., Masaki, K.H., Tanner, C.M., Curb, J.D., Grandinetti, A., Blanchette, P.L., Popper, J.S., Ross, G.W., Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57:3 (2001), 456–462.
74. [74] Aroniadis, O.C., Brandt, L.J., Fecal microbiota transplantation: past, present and future. Curr. Opin. gastroenterology 29:1 (2013), 79–84.
75. [75] Borody, T.J., Khoruts, A., Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterology Hepatology 9:2 (2012), 88–96.
76. [76] Braak, H., Rüb, U., Gai, W., Del Tredici, K., Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110:5 (2003), 517–536.
77. [77] Collins, S.M., Surette, M., Bercik, P., The interplay between the intestinal microbiota and the brain. Nat. Rev. Microbiol. 10:11 (2012), 735–742.
78. [78] Borody, T., Leis, S., Campbell, J., Torres, M., Nowak, A., Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis (MS), American Journal of Gastroenterology. 2011, NATURE PUBLISHING GROUP, 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA, S352.
79. [79] Borody, T., Rosen, D., Torres, M., Campbell, J., Nowak, A., Myoclonus dystonia-affected by GI microbiota. Am. J. Gastroenterology, 106, 2011, S352.
80. [80] de Vos, W.M., de Vos, E.A., Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr. Rev. 70:Suppl 1 (2012), S45–S56.
81. [81] Stoessl, A.J., Etiology Parkinson's Dis. Can. J. neurological Sci. Le J. Can. des Sci. neurologiques 26:Suppl 2 (1999), S5–S12.
82. [82] Liu, B., Gao, H.M., Hong, J.S., Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ. Health Perspect. 111:8 (2003), 1065–1073.
83. [83] Jenner, P., Olanow, C.W., The pathogenesis of cell death in Parkinson's disease. Neurology 66:4 (2006), S24–S36 10.
84. [84] Logroscino, G., The role of early life environmental risk factors in Parkinson disease: what is the evidence?. Environ. Health Perspect., 2005, 1234–1238.
85. [85] Pierantozzi, M., Pietroiusti, A., Sancesario, G., Lunardi, G., Fedele, E., Giacomini, P., Frasca, S., Galante, A., Marciani, M., Stanzione, P., Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients. Neurol. Sci. 22:1 (2001), 89–91.
86. [86] Dobbs, R.J., Dobbs, S.M., Weller, C., Bjarnason, I.T., Oxlade, N.L., Charlett, A., Al-Janabi, M.A., Kerwin, R.W., Mahler, R.F., Price, A.B., Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Helicobacter 10:4 (2005), 267–275.
87. [87] Fiddian-Green, R.G., Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations. Neurology, 68(13), 2007, 1085 author reply 1085.
88. [88] Senkovich, O.A., Yin, J., Ekshyyan, V., Conant, C., Traylor, J., Adegboyega, P., McGee, D.J., Rhoads, R.E., Slepenkov, S., Testerman, T.L., Helicobacter pylori AlpA and AlpB bind host laminin and influence gastric inflammation in gerbils. Infect. Immun. 79:8 (2011), 3106–3116.
89. [89] Barker, R.A., Cahn, A.P., Parkinson's disease: an autoimmune process. Int. J. Neurosci. 43:1–2 (1988), 1–7.
90. [90] Wersinger, C., Sidhu, A., An inflammatory pathomechanism for Parkinson's disease?. Curr. Med. Chem. 13:5 (2006), 591–602.
91. [91] Arai, H., Furuya, T., Mizuno, Y., Mochizuki, H., Inflammation and infection in Parkinson's disease. Histology Histopathol. 21:6 (2006), 673–678.
92. [92] Ickenstein, G., Klotz, J., Langohr, H., Virus encephalitis with symptomatic Parkinson syndrome, diabetes insipidus and panhypopituitarism. Fortschritte Neurologie-Psychiatrie 67:10 (1999), 476–481.
93. [93] Maggi, P., de Mari, M., Moramarco, A., Fiorentino, G., Lamberti, P., Angarano, G., Parkinsonism in a patient with AIDS and cerebral opportunistic granulomatous lesions. Neurological Sci. official J. Italian Neurological Soc. Italian Soc. Clin. Neurophysiology 21:3 (2000), 173–176.
94. [94] Fazzini, E., Fleming, J., Fahn, S., Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. Mov. Disord. Official J. Mov. Disord. Soc. 7:2 (1992), 153–158.
95. [95] Nicolson, G.L., Systemic Intracellular Bacterial Infections (Mycoplasma, Chlamydia, Borrelia Species) in Neurodegenerative (MS, ALS, Alzheimer's) and Behavioral (Autistic Spectrum Disorders) Diseases. 2008.
96. [96] Alasia, D.D., Asekomeh, G.A., Unachuku, C.N., Parkinsonism induced by sepsis: a case report. Niger. J. Med. J. Natl. Assoc. Resid. Dr. Niger. 15:3 (2006), 333–336.
97. [97] Fiszer, U., Tomik, B., Grzesiowski, P., Krygowska-Wajs, A., Walory, J., Michalowska, M., Palasik, W., The antibodies against Bordetella pertussis in sera of patients with Parkinson's disease and other non-neurological diseases. Acta Neurol. Scand. 110:2 (2004), 113–117.
98. [98] Ogata, A., Tashiro, K., Nukuzuma, S., Nagashima, K., Hall, W.W., A rat model of Parkinson's disease induced by Japanese encephalitis virus. J. Neurovirology 3:2 (1997), 141–147.
99. [99] Beaman, B.L., Canfield, D., Anderson, J., Pate, B., Calne, D., Site-specific invasion of the basal ganglia by Nocardia asteroides GUH-2. Med. Microbiol. Immunol. 188:4 (2000), 161–168.
100. [100] Caldwell, K.A., Tucci, M.L., Armagost, J., Hodges, T.W., Chen, J., Memon, S.B., Blalock, J.E., DeLeon, S.M., Findlay, R.H., Ruan, Q., Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration. PLoS One, 4(10), 2009 e7227.
101. [101] Bu, X.L., Wang, X., Xiang, Y., Shen, L.L., Wang, Q.H., Liu, Y.H., Jiao, S.S., Wang, Y.R., Cao, H.Y., Yi, X., Liu, C.H., Deng, B., Yao, X.Q., Xu, Z.Q., Zhou, H.D., Wang, Y.J., The association between infectious burden and Parkinson's disease: a case-control study. Park. Relat. Disord. 21:8 (2015), 877–881.
102. [102] McNaught, K.S., Perl, D.P., Brownell, A.L., Olanow, C.W., Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurology 56:1 (2004), 149–162.
103. [103] Matsui, H., Ito, H., Taniguchi, Y., Inoue, H., Takeda, S., Takahashi, R., Proteasome inhibition in medaka brain induces the features of Parkinson's disease. J. Neurochem. 115:1 (2010), 178–187.
104. [104] Bing, G., Lu, X., Zheng, N., Jin, L., Floyd, R., Kim, H., Microglia Mediated Dopaminergic Cell Death in the Substantia Nigra: a New Animal Model for Parkinson's Disease, Free Radical Biology and Medicine. 1998, PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND, S44.
105. [105] Liu, M., Bing, G., Lipopolysaccharide animal models for Parkinson's disease. Parkinson's Dis., 2011, 2011, 327089.
106. [106] Brenner, S.R., Blue-green algae or cyanobacteria in the intestinal micro-flora may produce neurotoxins such as Beta-N-Methylamino-L-Alanine (BMAA) which may be related to development of amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson-Dementia-Complex in humans and Equine Motor Neuron Disease in horses. Med. hypotheses, 80(1), 2013, 103.
107. [107] Pablo, J., Banack, S.A., Cox, P.A., Johnson, T.E., Papapetropoulos, S., Bradley, W.G., Buck, A., Mash, D.C., Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol. Scand. 120:4 (2009), 216–225.
108. [108] Scheperjans, F., Pekkonen, E., Kaakkola, S., Auvinen, P., Linking smoking, coffee, urate, and Parkinson's disease - a role for gut microbiota?. J. Parkinson's Dis. 5:2 (2015), 255–262.